- Home
- XPON vs WINT Comparison
XPON vs WINT Comparison
Compare XPON & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- WINT
- Stock Information
- Founded
- XPON 2016
- WINT 1992
- Country
- XPON United States
- WINT United States
- Employees
- XPON N/A
- WINT N/A
- Industry
- XPON Electronic Components
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XPON Technology
- WINT Health Care
- Exchange
- XPON Nasdaq
- WINT Nasdaq
- Market Cap
- XPON 1.9M
- WINT 2.0M
- IPO Year
- XPON 2022
- WINT 1995
- Fundamental
- Price
- XPON $1.33
- WINT $0.12
- Analyst Decision
- XPON
- WINT Hold
- Analyst Count
- XPON 0
- WINT 1
- Target Price
- XPON N/A
- WINT $7.00
- AVG Volume (30 Days)
- XPON 312.5K
- WINT 7.3M
- Earning Date
- XPON 03-27-2025
- WINT 11-27-2024
- Dividend Yield
- XPON N/A
- WINT N/A
- EPS Growth
- XPON N/A
- WINT N/A
- EPS
- XPON N/A
- WINT N/A
- Revenue
- XPON $4,498,181.00
- WINT N/A
- Revenue This Year
- XPON N/A
- WINT N/A
- Revenue Next Year
- XPON $66.62
- WINT N/A
- P/E Ratio
- XPON N/A
- WINT N/A
- Revenue Growth
- XPON N/A
- WINT N/A
- 52 Week Low
- XPON $1.32
- WINT $0.11
- 52 Week High
- XPON $473.00
- WINT $14.75
- Technical
- Relative Strength Index (RSI)
- XPON 30.42
- WINT 15.60
- Support Level
- XPON $1.32
- WINT $0.21
- Resistance Level
- XPON $1.75
- WINT $0.33
- Average True Range (ATR)
- XPON 0.10
- WINT 0.03
- MACD
- XPON -0.01
- WINT 0.00
- Stochastic Oscillator
- XPON 2.18
- WINT 2.15
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.